Evolution of treatment strategies in multiple myeloma

Clinical and Laboratory Haematology

Volumn 20, Issue 4, 1998, Pages 199-206

  Owen, R G ^a,b   Morgan, G J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Multiple myeloma; Treatment

Indexed keywords

ALPHA INTERFERON; BENCE JONES PROTEIN; CORTICOSTEROID; DAUNORUBICIN; ERYTHROPOIETIN; IDARUBICIN; IMEXON; IMMUNOGLOBULIN; INTERLEUKIN 6; MELPHALAN; NAVELBINE; TOPOTECAN;

AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; EVOLUTION; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT PLANNING;

HUMANS; MULTIPLE MYELOMA;

EID: 0031660207     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1998.00174.x     Document Type: Review

References (93)

1. Alexanian R. (1980) Localized and indolent myeloma. Blood 56, 521-525.
2. Alexanian R. & Dimopoulos M.A. (1994) The treatment of multiple myeloma. New England Journal of Medicine 330, 484-489.
3. Alexanian R. & Dimopoulos M.A. (1995) Management of multiple myeloma. Seminars in Haematology 32, 20-30.
4. Anderson K.C., Anderson J., Soiffer R. et al. (1993) Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82, 2568-2576.
5. Attal M., Harousseau J.L., Stoppa A.M. et al. (1996) A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine 335, 91-97.
6. Attal M., Payen C., Facon T. et al. (1997) Single versus double transplant in myeloma: a randomized trial of the Intergroupe Francais du Myelome. Blood, 90 (Suppl. 1), 1859.
7. Barlogie B., Jaganath S., Vesole D.H. et al. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89, 789-793.
8. Barlogie B., Jaganath S., Vesole D. & Tricot G. (1995) Autologous and allogeneic transplants for multiple myeloma. Seminars in Haematology 32, 31-44.
9. Barlogie B., Smith L. & Alexanian R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine 310, 1353-1356.
10. Bataille R., Grenier J. & Sany J. (1984) Beta-2-microglobulin in myeloma: optimal use for staging, prognosis and treatment - a prospective study of 160 patients. Blood 63, 468-476.
11. Belch A.R., Bergsagel D.E., Wilson K. et al. (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology 9, 1397-1402.
12. Bence Jones H. (1847) Chemical Pathology. Lancet 2, 88-92.
13. Bensinger W.I., Buckner C.D., Anasetti C. et al. (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88, 2787-2793.
14. Berenson J.R., Lichtenstein A., Porter L. et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine 334, 488-493.
15. Berenson J., Lichtenstein A., Porter L. et al. (1995) Long-term pamidronate disodium therapy leads to a reduction of skeletal related episodes (SREs) in stage III multiple myeloma patients and an improvement in survival in those on salvage therapy. Bone 17, 614-616.
16. Bergsagel D.E., Sprague C.C., Austin C. & Griffith K.M. (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21, 87-89.
17. Bertz H., Burger J.A., Kunzmann R., Mertelsman R. & Finke J. (1997) Adoptive immunotherapy for relapsed multiple myeloma after allogeneic marrow transplantation (BMT): evidence of a graft versus myeloma effect. Leukemia 11, 281-283.
18. Bird J.M., Bloxham D., Samson D. et al. (1994) Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. British Journal of Haematology 88, 110-116.
19. Bird J.M., Russell N.H. & Samson D. (1993) Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long term survivors. Bone Marrow Transplantation 12, 651-654.
20. Bjorkstrand B., Goldstone A.H., Ljungman P. et al. (1994) Prognostic factors in autologous stem cell transplantation for mutiple myeloma: an EBMT registry study. Leukemia and Lymphoma 15, 265-272.
21. Bjorkstrand B., Ljungman P., Bird J.M., Samson D. & Gharton G. (1995) Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplantation 15, 367-371.
22. Bjorkstrand B., Ljungman P., Svensson H. et al. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88, 4711-4718.
23. Blade J., Lopez-Guillermo A., Bosch F. et al. (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology 88, 117-121.
24. Boccadoro M., Marmont F., Tribalto M. et al. (1991) Multiple myeloma: VMCP/VBAP alternating combination is not superior to melphalan and prednisone even in high risk patients. Journal of Clinical Oncology 9, 444-448.
25. Bonin C., Ferrari G., Verzeletti S. et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus host disease. Science 276, 1719-1724.
26. Brenner M.K., Rill D.R., Moen R.C. et al. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341, 85-86.
27. Cazzola M., Messinger D., Battistel V. et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86, 4446-4453.
28. Chapel H.M., Lee M., Hargreaves R., Pamphilon D.H. & Prentice A.G. (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 343, 1059-1063.
29. Cook G., Lee F.D., Farquarson M., Pearson C., Tansey P. & Franklin I.M. (1996) Detection of minimal residual disease using kappa/lambda mRNA in-situ hybridisation post autologous peripheral blood progenitor cell transplantation (PBPCT) in patients with multiple myeloma. British Journal of Haematology 93 (Suppl. 1), 55a.
30. Corradini P., Voena C., Astolfi M. et al. (1995) High-dose sequential chemoradiotherapy in mutiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85, 1596-1602.
31. Dalrymple J. (1846) On the microscopical character of mollities ossium. Dublin Quarterly Journal of Medical Science 2, 85-95.
32. Dimopoulos M.A., Moulopoulos A., Smith T., Delasalle K.B. & Alexanian R. (1993) Risk of disease progression in asymptomatic multiple myeloma. American Journal of Medicine 94, 57-61.
33. Durie B.G.M., Gale R.P., Klein J.P., Pelz C., Nugent M.L. & Horowitz M.M. (1995) Allogeneic bone marrow transplantation in multiple myeloma: an IBMTR analysis. Proceeding of the Vth International Workshop on Multiple Myeloma, p128.
34. Durie B.G.M. & Salmon S.E. (1975) A clinical staging system for multiple myeloma. Cancer 36, 842-854.
35. Gazitt Y., Reading C.C., Hoffman R. et al. (1995) Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood 86, 381-389.
36. Gharton G., Tura S., Ljungman P. et al. (1995) Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology 13, 1312-1322.
37. Gianni A.M., Tarella C., Bregni M. et al. (1994) High-dose sequential chemoradiotherapy, a widely applicable regimen, confers a survival benefit to patients with high-risk multiple myeloma. Journal of Clinical Oncology 12, 503-509.
38. Giralt S., Weber D., Colome M. et al. (1997) Phase 1 trial of cyclosporine induced autologous graft versus host disease in patients with multiple myeloma undergoing high dose chemotherapy with autologous stem cell rescue. Journal of Clinical Oncology 15, 667-673.
39. Gobbi M., Cavo M., Tazzari P.L. et al. (1989) Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. European Journal of Haematology 43 (Suppl. 51), 176-181.
40. Gore M.E., Selby P.J., Viner C. et al. (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet ii, 879-881.
41. Gregory W.M., Richards M.A. & Malpas J.S. (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology 10, 334-342.
42. Gribben J.G., Saporito L., Barber M. et al. (1992) Bone marrows of Non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80, 1083-1089.
43. Harousseau J.L., Attal M., Divine M. et al. (1995a) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 85, 3077-3085.
44. Harousseau J.L., Attal M., Divine M. et al. (1995b) Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplantation 15, 965-969.
45. Hawkins R.E., Zhu D., Ovecka M. et al. (1994) Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83, 3279-3288.
46. Hoover R.G. (1995) Gene therapy for multiple myeloma with soluble CD16. Proceedings of the Vth International Workshop on Multiple Myeloma, p134.
47. Hsu F.J., Benike C., Fagnoni F. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nature Medicine 2, 52-58.
48. Hsu F.J., Caspar C.B., Czerwinski D. et al. (1997) Tumour-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135.
49. Johnson R.J., Owen R.G., Smith G.M. et al. (1996) Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplantation 17, 723-727.
50. Johnson P.W.M. & Selby P.J. (1994) The treatment of multiple myeloma - an important MRC trial. British Journal of Cancer 70, 781-785.
51. Kanis J.A., McCloskey E.V., Taube T. & O'Rourke N. (1991) Rationale for the use of bisphosphonates in bone metastases. Bone 12 (Suppl. 1), 13-18.
52. Klein B., Zhang X.G., Lu Z.Y. & Bataille R. (1995) Interleukin-6 in human multiple myeloma. Blood 85, 863-872.
53. Kwak L.W., Taub D.D., Duffey P.L. et al. (1995) Transfer of myeloma idiotype specific immunity from an actively immunised donor. Lancet 345, 1016-1020.
54. Kyle R.A. & Greipp P.R. (1980) Smouldering multiple myeloma. New England Journal of Medicine 302, 1347-1349.
55. Lahtinen R., Laakso M., Palva I., Virkkunen P. & Elomaa I. (1992) Randomised, placebo-controlled multicentre trial of clodronate in mutiple myeloma. Lancet 340, 1049-1052.
56. Lemoli R.M., Fortuna A., Motta M.R. et al. (1996) Concomitant mobilization of plasma cells and haemopoietic progenitors into peripheral blood of multiple myeloma patients; positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87, 1625-1634.
57. Ludwig H., Cohen A.M., Polliack A. et al. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology 6, 467-476.
58. Ludwig H., Fitz E., Neuda J. & Durie B.G. (1997) Patient preferences for interferon alfa in multiple myeloma. Journal of Clinical Oncology 15, 1672-1679.
59. Ludwig H., Fritz E., Leitgeb C. et al. (1993) Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Annals of Oncology 4, 161-167.
60. MacIntyre W. (1850) Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans Lond 33, 211-232.
61. Majolino I., Pearce R., Taghipour G. & Goldstone A.H. (1995) PBSCT vs ABMT in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the EBMT registry data. Bone Marrow Transplantation 15 (Suppl. 2), 162a.
62. Mandelli F., Avvisati G., Amadori S. et al. (1990) Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine 322, 1430-1434.
63. Massaia M., Borrione P., Beggiato E. et al. (1995) T cells and immunotherapy in multiple myeloma: a rational approach. Proceedings of the Vth International Workshop on Multiple Myeloma, p 130.
64. McCloskey E.V., MacLennan I.C.M., Drayson M.T., Chapman C., Dunn J. & Kanis J.A. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology 100, 317-325.
65. McElwain T.J. & Powles R.J. (1983) High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet ii, 822-824.
66. Mundy G.R., Raisz L.G., Cooper R.A., Schechter G.P. & Salmon S. (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine 291, 1041-1046.
67. Musto P., Brugiatelli M. & Carotenuto M. (1995) Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. British Journal of Haematology 89, 945-946.
68. Osterborg A., Boogaerts M.A., Cimino R. et al. (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a multicenter study. Blood 87, 2675-2682.
69. Owen R.G., Bybee A., Haynes A.P. et al. (1996c) PCR assessment of MRD following transplantation in multiple myeloma. British Journal of Haematology 93 (Suppl. 1), 44a.
70. Owen R.G., Haynes A.P., Evans P.A. et al. (1996a) Detection of clonal immunoglobulin gene rearrangements in the PBPC of patients with multiple myeloma - the potential role of purging with CD34 positive selection. Journal of Clinical Pathology: Clinical Molecular Pathology 49, 112-117.
71. Owen R.G., Johnson R.J., Rawstron A. et al. (1996b) Assessment of IgH PCR strategies in multiple myeloma. Journal of Clinical Pathology 49, 672-675.
72. Powles R., Rage N., Cunningham D. et al. (1995) Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow trasplant or peripheral blood stem cell rescue. Stem Cells 13 (Suppl. 2), 114-117.
73. Ralph Q.M., Brisco M.J., Joshua D.E., Brown R., Gibson J. & Morley A.A. (1993) Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 82, 202-206.
74. Rawstron A.C., Owen R.G., Davies F.E. et al. (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British Journal of Haematology 97, 46-55.
75. Rettig M.B., Ma H.J., Vescio R.A. et al. (1997) Kaposi's sarcoma-associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276, 1851-1854.
76. Rill D.R., Santana V.M., Roberts W.M., Nilson T., Bowman L.C. & Krance R.A. (1994) Direct demonstration that autologous bone marrow transplantation for solid tumours can return a multiplicity of tumorigenic cells. Blood 84, 380-383.
77. Rowley S.D., Piantadosi S., Marcellus D.C. et al. (1991) Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. Bone Marrow Transplantation 7, 183-191.
78. Russell N.H., Millin G., Stainer C. et al. (1997) Allogeneic bone marrow transplant for multiple myeloma. Blood 89, 2610-2611.
79. Samson D., Volin L., Schanz U., Bosi A. & Gahrton G. (1996) Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma. Bone Marrow Transplantation 17, 759-762.
80. Schiller G., Vescio R., Freytes C. et al. (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86, 390-397.
81. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G.G. & Croucher P.I. (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Activity Journal of Haematology 98, 665-672.
82. Sporeno E., Savina R., Ciapponi L. et al. (1996) Human interleukin-6 super-antagonists with high potency and wide spectrum on multiple myeloma cell. Blood 87, 4510-4519.
83. Stirpe F., Barbieri L., Tazzari P.L., Dinota A. & Gobbi M. (1989) Ex vivo bone marrow purging with immunotoxins. European Journal of Haematology 43 (Suppl. 51), 173-175.
84. Tarin F., Orero M., Miguel Garcia A. et al. (1997) Prognosis value of the monoclonal blood plasma cells in multiple myeloma. Blood 89, 3065-3066.
85. Tricot G., Barlogie B., Jagannath S. et al. (1995) Double autotransplants can induce molecular remissions (MCR) in newly diagnosed patients with multiple myeloma. Blood 86 (Suppl. 1), 969a.
86. Tricot G., Vesole D.H., Jaganath S., Hilton J., Munshi N. & Barlogie B. (1996) Graft versus myeloma effect: proof of principle. Blood 87, 1196-1198.
87. Verdonck L.F., Lokhorst H.M., Dekker A.W., Niewenhuis K, & Peterson E.J. (1996) Graft versus myeloma effect in two cases. Lancet 347, 800-801.
88. Vescio R.A., Han E.J., Schiller G.J. et al. (1996) Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplantation 18, 103-110.
89. Vescio R.A., Hong C.H., Cao J. et al. (1994) The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 84, 3283-3290.
90. Vesole D.H., Tricot G., Jaganath S. et al. (1996) Autotransplants in multiple myeloma: what have we learned? Blood 88, 838-847.
91. Von Rustisky J. (1873) Multiples myelom. Dtsch Z Chir 3, 162-172.
92. Witzig T.E., Gertz M.A., Lust J.A., Kyle R.A., O'Fallon W.M. & Greipp P.R. (1996b) Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88, 1780-1787.
93. Witzig T.E., Kimlinger T.K., Ahmann G.J., Katzmann J.A. & Greipp P.R. (1996a) Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26, 113-120.